Mirum Pharmaceuticals, Inc.
Clinical trials sponsored by Mirum Pharmaceuticals, Inc., explained in plain language.
-
New hope for rare liver disease: experimental drug shows promise
Disease control OngoingThis study tests a new medicine called BJT-778 for people with chronic hepatitis delta, a serious liver infection. About 150 adults will either start the drug right away or wait 24 weeks before starting it. The goal is to see if the drug can lower the virus level and improve live…
Phase: PHASE2, PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for rare liver itch: phase 3 drug trial underway
Symptom relief OngoingThis study tests a drug called maralixibat for people with rare liver diseases who suffer from severe itching that hasn't responded to other treatments. About 90 children and adults will receive either the drug or a placebo to see if it safely reduces itching. The goal is to impr…
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated May 17, 2026 05:53 UTC
-
New drug offers hope for relentless itching in rare liver disease
Symptom relief OngoingThis study tests a medicine called volixibat to see if it can reduce severe itching caused by primary sclerosing cholangitis (PSC), a rare liver disease. About 182 people aged 12 and older with PSC-related itching will receive either volixibat or a placebo. The main goal is to me…
Phase: PHASE2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated May 14, 2026 12:05 UTC